Celularity expects Q4 biomaterial/biobanking net sales up 176–193% YoY, full year up 23–27%

Celularity Inc

2023-FY EPS reported -$11.02 revenue$22,771,000

Q4 2023 net sales expected $11.4M–$12.1M, up 176–193% vs Q4 2022.
Full year 2023 net sales expected $22.06M–$22.76M, up 23–27% vs FY 2022.
Excludes other revenue, including the Regeneron research collaboration agreement.
Company plans to provide 2024 revenue guidance soon; aims to boost cash flow from commercial products.
Actual Q4 and FY 2023 net sales and total revenue to be announced later in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celularity Inc reported fourth quarter 2023 results: revenue expected net sales ... to be in the range of $11.4 million to $12.1 million. Guidance reaffirmed.

Period: fourth quarter 2023
Revenue: expected net sales ... to be in the range of $11.4 million to $12.1 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Total Revenue Expectations for Fourth Quarter 2023 and Full Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Celularity Inc reported full year 2023 results: revenue expected net sales ... to be in the range of $22.06 million to $22.76 million. Guidance reaffirmed.

Period: full year 2023
Revenue: expected net sales ... to be in the range of $22.06 million to $22.76 million
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Year 2023 Celularity expects net sales of its biomaterial products and biobanking businesses to be in the range of $11.4 million to $12.1 million for the fourth quarter 2023 and $22.06 million to $22.76 million for the full year 2023 reflecting triple-digit increases compared to the fourth quarter 2022 and full year 2022, respectively. These numbers do not include

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Celularity Inc filing history →

Source: SEC EDGAR

accession 0000950170-24-003387

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.